Dr. Laubach is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Avenue
Boston, MA 02115Phone+1 617-632-4218Fax+1 617-582-8608- Is this information wrong?
Education & Training
- Duke University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008
- Duke University HospitalResidency, Internal Medicine, 1999 - 2002
- Duke University School of MedicineClass of 1999
Certifications & Licensure
- MA State Medical License 2008 - 2025
- NH State Medical License 2023 - 2025
- NC State Medical License 1999 - 2009
- American Board of Internal Medicine Hematology
Clinical Trials
- Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro Start of enrollment: 2010 Oct 01
- Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2012 May 01
- XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease Start of enrollment: 2012 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 308 citationsTumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humansGullu Gorgun, Gregory Whitehill, Jennifer L. Anderson, Teru Hideshima, Craig Maguire
Blood. 2013-04-11 - 102 citationsKidney Disease and Multiple MyelomaEliot Heher, Helmut G. Rennke, Jacob P. Laubach, Paul G. Richardson
Clinical Journal of the American Society of Nephrology. 2013-11-07 - 725 citationsOral Ixazomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPhilippe Moreau, Tamás Masszi, Norbert Grzasko, Nizar J. Bahlis, Markus Hansson
The New England Journal of Medicine. 2016-04-27
Abstracts/Posters
- Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of OncoproteinsJacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple MyelomaJacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple MyelomaJacob P. Laubach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Improving Rates of Venous Thromboembolism Prophylaxis in Multiple Myeloma Patients on Immunomodulatory Drugs2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoprotein...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- GRIFFIN: Daratumumab Combination Maintains Deep Durable Response in Transplant-Eligible MyelomaDecember 13th, 2021
- (Daratumumab) in Patients with Newly Diagnosed Multiple MyelomaDecember 11th, 2021
- Treatment Trio Soars in New Transplant-Ineligible MMNovember 18th, 2021
- Join now to see all
Hospital Affiliations
- Brigham and Women's HospitalBoston, Massachusetts
- Salem HospitalSalem, Massachusetts
- Dana-Farber Cancer InstituteBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: